Ben Fidler
Senior Editor | @BentheFidlerBen is a senior editor for BioPharma Dive. He is a veteran business journalist with 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
795 articles by Ben Fidler
-
Drugs from China are reshaping biotech. Track the licensing deals here.
Aug. 25, 2025 -
Xoma, a drug royalty specialist, buys another ‘zombie’ biotech
Aug. 20, 2025 -
Novo’s Wegovy becomes first GLP-1 drug approved for MASH
Aug. 18, 2025 -
Vedanta, PureTech’s microbiome startup, to cut staff after study setback
Aug. 14, 2025 -
Expedition, a startup searching for drugs from China, cuts its first deal
Aug. 12, 2025 -
Novartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune disease
Aug. 11, 2025 -
Vinay Prasad, in surprise reversal, to rejoin FDA after abrupt departure
Aug. 9, 2025 -
FDA to start new ‘precheck’ program to boost US drug production
Aug. 7, 2025 -
Iovance cuts staff amid slow sales start for ‘TIL’ cell therapy
Aug. 7, 2025 -
US biotech needs government support to match China’s gains, Pfizer CEO says
Aug. 5, 2025 -
David Altshuler, geneticist who helped transform Vertex, to retire next year
Aug. 5, 2025 -
Alnylam reaches new highs on strong sales of closely watched rare disease drug
July 31, 2025 -
Vinay Prasad’s ouster leaves biotech guessing at FDA direction
July 30, 2025 -
Vinay Prasad, controversial FDA official, abruptly departs agency
July 29, 2025 -
Bain leads $300M investment in startup built on Bristol Myers immune drugs
July 29, 2025 -
FDA allows Sarepta to resume some Elevidys shipments
July 28, 2025 -
GSK pays $500M to enter drugmaking alliance with Hengrui
July 28, 2025 -
Sarepta woes mount as Duchenne gene therapy knocked back in Europe
July 25, 2025 -
AstraZeneca drug acquired in Alexion deal succeeds in autoimmune disease trial
July 24, 2025 -
Dispatch emerges with $216M and plans for a ‘universal’ solid tumor therapy
July 23, 2025 -
5 questions on Sarepta, the FDA and a Duchenne gene therapy crisis
July 21, 2025 -
Sarepta reports patient death in limb-girdle trial, compounding concerns on gene therapy risks
July 18, 2025 -
Bristol Myers, Pfizer to offer Eliquis at a discount for some patients
July 17, 2025 -
Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks
July 16, 2025 -
33 states pick up CMS program to pay for sickle cell gene therapies
July 16, 2025